Cargando…

Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

Detalles Bibliográficos
Autores principales:	Nie, Lei, Wei, Yongkun, Zhang, Fei, Hsu, Yi-Hsin, Chan, Li-Chuan, Xia, Weiya, Ke, Baozhen, Zhu, Cihui, Deng, Rong, Tang, Jun, Yao, Jun, Chu, Yu-Yi, Zhao, Xixi, Han, Ye, Hou, Junwei, Huo, Longfei, Ko, How-Wen, Lin, Wan-Chi, Yamaguchi, Hirohito, Hsu, Jung-Mao, Yang, Yi, Pan, Dean N., Hsu, Jennifer L., Kleer, Celina G., Davidson, Nancy E., Hortobagyi, Gabriel N., Hung, Mien-Chie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989459/ https://www.ncbi.nlm.nih.gov/pubmed/31996688 http://dx.doi.org/10.1038/s41467-020-14429-3

Ejemplares similares

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Nie, Lei, et al.
Publicado: (2019)

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2017)

GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers
por: Ko, How-Wen, et al.
Publicado: (2016)

Regulation and Role of EZH2 in Cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2014)

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
por: Yam, Clinton, et al.
Publicado: (2018)

Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex
por: Chu, Yu-Yi, et al.
Publicado: (2022)

Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2012)

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment
por: Jiang, Zhou, et al.
Publicado: (2020)

An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response
por: Wang, Ying-Nai, et al.
Publicado: (2022)

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
por: Du, Yi, et al.
Publicado: (2016)

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
por: Chu, Yu-Yi, et al.
Publicado: (2022)

PD-L1-Mediated Gasdermin C Expression Switches Apoptosis to Pyroptosis in Cancer Cells and Facilitates Tumor Necrosis
por: Hou, Junwei, et al.
Publicado: (2020)

Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation
por: Lee, Heng-Huan, et al.
Publicado: (2021)

EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer
por: Debeb, Bisrat G, et al.
Publicado: (2014)

Cyclin-dependent Kinase 1 (CDK1)-mediated Phosphorylation of Enhancer of Zeste 2 (Ezh2) Regulates Its Stability
por: Wu, Susan C., et al.
Publicado: (2011)

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer
por: Qiu, Yufan, et al.
Publicado: (2021)

Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
por: Lin, Yueh-Te, et al.
Publicado: (2021)

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
por: Li, Chia-Wei, et al.
Publicado: (2016)

Herbal Compounds Dauricine and Isoliensinine Impede SARS-CoV-2 Viral Entry
por: Dabrell, Shaneek Natoya, et al.
Publicado: (2023)

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
por: Hsu, Jung-Mao, et al.
Publicado: (2018)

Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer
por: Cha, Jong-Ho, et al.
Publicado: (2022)

Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke
por: Yu, Yung-Luen, et al.
Publicado: (2013)

Isolation of cancer-derived extracellular vesicle subpopulations by a size-selective microfluidic platform
por: Chen, Zheyuan, et al.
Publicado: (2020)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Activation of phagocytosis by immune checkpoint blockade
por: Li, Chia-Wei, et al.
Publicado: (2018)

Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity
por: Sun, Xian, et al.
Publicado: (2023)

p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis
por: Anwar, Talha, et al.
Publicado: (2018)

EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression
por: Lin, Zong-Shin, et al.
Publicado: (2023)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma
por: Xie, Shao, et al.
Publicado: (2020)

Sulforaphane-Induced Cell Mitotic Delay and Inhibited Cell Proliferation via Regulating CDK5R1 Upregulation in Breast Cancer Cell Lines
por: Hung, Chao-Ming, et al.
Publicado: (2023)

EZH2 is a potential prognostic predictor of glioma
por: Chen, Yi‐nan, et al.
Publicado: (2020)

Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells
por: Nakayama, Satoshi, et al.
Publicado: (2009)

Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo
por: Tang, Shou-Hung, et al.
Publicado: (2014)

EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression
por: Gonzalez, Maria E., et al.
Publicado: (2022)

The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
por: Wang, Ying-Nai, et al.
Publicado: (2020)

Tanshinone I, a new EZH2 inhibitor restricts normal and malignant hematopoiesis through upregulation of MMP9 and ABCG2
por: Huang, Ying, et al.
Publicado: (2021)

Regulation of senescence escape by the cdk4–EZH2–AP2M1 pathway in response to chemotherapy
por: Le Duff, Mélanie, et al.
Publicado: (2018)

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies
por: Mei, Husheng, et al.
Publicado: (2023)

The noncanonical role of EZH2 in cancer
por: Huang, Jinhua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2d2alqmhjeolh4ck4qtekh9r7f